Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis

Area of Science:

• Neurology
• Molecular Biology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no effective treatments.
• Genetic discoveries have identified targets for familial ALS, including SOD1 mutations and C9orf72 repeat expansions.
• Sporadic ALS (sALS) also presents potential targets for molecular therapies.

Purpose of the Study:

• To review the progress of molecular therapies for ALS currently in clinical trials.
• To highlight promising antisense oligonucleotide (ASO) and viral therapeutic strategies for ALS treatment.
• To discuss the potential of ASO and viral therapies based on recent findings and preclinical/clinical studies.

Main Methods:

• Review of current clinical trial pipelines for ALS molecular therapies.
• Analysis of preclinical and clinical data for ASO-based therapies targeting SOD1 and C9orf72.
• Evaluation of adeno-associated virus (AAV)-based therapeutic strategies and their application to ALS.

Main Results:

• Significant progress in ASO therapy development for genetic forms of ALS.
• Preclinical studies identify promising targets for sporadic ALS.
• Positive outcomes from AAV-based therapies in related neuromuscular diseases (e.g., SMA) inform ALS therapy design.

Conclusions:

• ASO and viral-directed therapies demonstrate high specificity and good tolerability in preclinical and clinical studies for neuromuscular diseases like ALS.
• These molecular approaches represent a promising future direction for ALS treatment.
• Advances in genetic understanding and therapeutic delivery are crucial for developing effective ALS therapies.